Adamas Pharmaceuticals Inc (ADMS):企業の財務・戦略的SWOT分析

◆英語タイトル:Adamas Pharmaceuticals Inc (ADMS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C3054
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Adamas Pharmaceuticals Inc (ADMS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company’s Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment for dyskinesia in patients with Parkinson’s disease. Gocovri is a high-dose, once-daily indication designed to deliver high level of amantadine in the morning and throughout the day when dyskinesia occurs. Its pipeline includes ADS-5102 for the treatment of wearing OFF, and delaying motor complications in Parkinson’s disease; Huntington’s chorea; tardive dyskinesia; non-motor disorders, including depression, and anti-psychotic induced weight gain; and Tourette syndrome; and various others indications; and ADS-4101 in Phase 3 for the treatment of partial onset seizures in patients with epilepsy. The company also offers namzaric and namenda XR for the treatment of moderate to severe Alzheimer’s disease. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.

Adamas Pharmaceuticals Inc Key Recent Developments

Aug 02,2018: Adamas announces second quarter 2018 financial results
May 03,2018: Adamas Reports First Quarter 2018 Financial Results
Feb 22,2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
Nov 02,2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
Oct 11,2017: Adamas appoints Mardi C Dier to its board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Adamas Pharmaceuticals Inc – Key Facts 5
Adamas Pharmaceuticals Inc – Key Employees 6
Adamas Pharmaceuticals Inc – Major Products and Services 7
Adamas Pharmaceuticals Inc – History 8
Adamas Pharmaceuticals Inc – Company Statement 9
Adamas Pharmaceuticals Inc – Locations And Subsidiaries 11
Head Office 11
Section 2 – Company Analysis 12
Company Overview 12
Adamas Pharmaceuticals Inc – Business Description 13
R&D Overview 13
Adamas Pharmaceuticals Inc – Corporate Strategy 14
Adamas Pharmaceuticals Inc – SWOT Analysis 15
SWOT Analysis – Overview 15
Adamas Pharmaceuticals Inc – Strengths 15
Adamas Pharmaceuticals Inc – Weaknesses 16
Adamas Pharmaceuticals Inc – Opportunities 17
Adamas Pharmaceuticals Inc – Threats 18
Adamas Pharmaceuticals Inc – Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios – Capital Market Ratios 20
Financial Ratios – Annual Ratios 21
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Adamas Pharmaceuticals Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
May 03, 2018: Adamas Reports First Quarter 2018 Financial Results 30
Feb 22, 2018: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017 31
Nov 02, 2017: Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results 33
Aug 08, 2017: Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results 35
Jun 28, 2017: Adamas Appoints New Chief Financial Officer 37
May 09, 2017: Adamas Reports Recent Achievements and First Quarter 2017 Financial Results 38
Apr 27, 2017: Adamas Pharmaceuticals appoints new COO 39
Feb 28, 2017: Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016 40
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Adamas Pharmaceuticals Inc, Key Facts 5
Adamas Pharmaceuticals Inc, Key Employees 6
Adamas Pharmaceuticals Inc, Major Products and Services 7
Adamas Pharmaceuticals Inc, History 8
Adamas Pharmaceuticals Inc, Key Competitors 19
Adamas Pharmaceuticals Inc, Ratios based on current share price 20
Adamas Pharmaceuticals Inc, Annual Ratios 21
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...1) 22
Adamas Pharmaceuticals Inc, Annual Ratios (Cont...2) 23
Adamas Pharmaceuticals Inc, Interim Ratios 25
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Adamas Pharmaceuticals Inc, Recent Deals Summary 29
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45

List of Figures
Adamas Pharmaceuticals Inc, Performance Chart (2013 - 2017) 24
Adamas Pharmaceuticals Inc, Ratio Charts 26
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Adamas Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★海外企業調査レポート[Adamas Pharmaceuticals Inc (ADMS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aiful Corporation:企業の戦略・SWOT・財務情報
    Aiful Corporation - Strategy, SWOT and Corporate Finance Report Summary Aiful Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Drexel University:製薬・医療:M&Aディール及び事業提携情報
    Summary Drexel University (Drexel) is a research university which provides educational degrees and research programs. The university offers courses for undergraduate courses, graduate and professional courses, adult education programs, colleges and schools, libraries and online training services. It …
  • Westminster Group plc:企業の戦略・SWOT・財務分析
    Westminster Group plc - Strategy, SWOT and Corporate Finance Report Summary Westminster Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • NHPC Ltd (NHPC):企業の財務・戦略的SWOT分析
    NHPC Ltd (NHPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Triphase Accelerator Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Triphase Accelerator Corp (Triphase Accelerator) is a biotechnology development company that acquires and develops novel therapeutics for the treatment of cancer. The company's pipeline products comprise marizomib, a brain-penetrant proteasome inhibitor, which is developed in both intravenou …
  • New Carolin Gold Corp:企業の戦略・SWOT・財務情報
    New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report Summary New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Troy Resources Limited:企業の戦略・SWOT・財務分析
    Troy Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Troy Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Honeywell International Inc (HON):石油・ガス:M&Aディール及び事業提携情報
    Summary Honeywell International Inc. (Honeywell) is a diversified manufacturing and technology company. The company offers avionics, aircraft engines, systems and service solutions; environmental and combustion controls, sensing controls, security and life safety products and services, scanning and …
  • Cosmo Oil Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Cosmo Oil Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Cosmo Oil Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the o …
  • Immune Pharmaceuticals Inc (IMNP):企業の財務・戦略的SWOT分析
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • Modernizing Medicine Inc:医療機器:M&Aディール及び事業提携情報
    Summary Modernizing Medicine Inc (MMI) is a technology company that offers healthcare electronic health records (EHR) solutions. The company offers data management system and electronic medical record systems in the areas of gastroenterology, ophthalmology, orthopedics, otolaryngology, pain manageme …
  • Dynatronics Corp (DYNT):医療機器:M&Aディール及び事業提携情報
    Summary Dynatronics Corp (Dynatronics) is a medical device company that offers rehab technology and equipment solutions. The company offers modalities, hot and cold therapy, clinical accessories, body positioning, sports medicine, orthopedics, hand therapy, strength equipment, treatment tables and r …
  • Air Liquide SA:企業の戦略・SWOT・財務情報
    Air Liquide SA - Strategy, SWOT and Corporate Finance Report Summary Air Liquide SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • UGI Corporation:企業の戦略・SWOT・財務情報
    UGI Corporation - Strategy, SWOT and Corporate Finance Report Summary UGI Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Valeant Pharmaceuticals International, Inc.:企業のM&A・事業提携・投資動向
    Valeant Pharmaceuticals International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Valeant Pharmaceuticals International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • KnowBe4 Inc:企業の戦略的SWOT分析
    KnowBe4 Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • SM Energy Company:企業の戦略・SWOT・財務分析
    SM Energy Company - Strategy, SWOT and Corporate Finance Report Summary SM Energy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Mediobanca – Banca di Credito Finanziario SpA (MB):企業の財務・戦略的SWOT分析
    Mediobanca - Banca di Credito Finanziario SpA (MB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • PT Tiphone Mobile Indonesia Tbk (TELE):企業の財務・戦略的SWOT分析
    PT Tiphone Mobile Indonesia Tbk (TELE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Deutsche Telekom AG (DTE):企業の財務・戦略的SWOT分析
    Deutsche Telekom AG (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆